CD8A and cancer: The dependence of TERT expression on all three signaling pathways with IL-2 and with IL-15 in CD8 T cells, suggests that any therapies that inhibit MEK/ERK pathways used in cancer patients are likely to affect proliferation of CD8 T cells to a greater extent than NK cells or NK-like cells.